Core Insights - Metsera (MTSR.US) experienced a pre-market decline of over 2.2%, trading at $79.71 after reaching a historical high of $82.79 with an intraday increase of nearly 16% the previous day [1] - Novo Nordisk has raised its acquisition bid for Metsera in response to Pfizer's increased offer, which reached a maximum of $86.2 per share [1] - Metsera's new generation weight loss drug has shown good tolerability in mid-stage clinical trials, with weight loss effects comparable to Eli Lilly's Zepbound [1] - Data from late September indicated that participants in the trial experienced an average weight loss of 14.1% after 28 weeks of weekly injections, with low incidence rates of nausea and vomiting [1]